Mira Pharmaceuticals annual return on equity
2023
2024
2025
Mira Pharmaceuticals Return on Equity (ROE) Growth & History (MIRA)
Mira Pharmaceuticals's return on equity was −165.87% for fiscal 2025.
View full Mira Pharmaceuticals company overviewMira Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −165.87% | +73.03 pp |
| 2024 | 2024-12-31 | −238.90% | +395.41 pp |
| 2023 | 2023-12-31 | −634.30% | — |
Mira Pharmaceuticals quarterly return on equity
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −13.80% | +151.19 pp |
| Q1 2026 | 2026-03-31 | −11.65% | +90.46 pp |
| Q4 2025 | 2025-12-31 | −66.70% | +16.43 pp |
| Q3 2025 | 2025-09-30 | −28.02% | +42.54 pp |
| Q2 2025 | 2025-06-30 | −164.99% | −102.06 pp |
| Q1 2025 | 2025-03-31 | −102.11% | −56.49 pp |
| Q4 2024 | 2024-12-31 | −83.13% | +9.55 pp |
| Q3 2024 | 2024-09-30 | −70.57% | +6.49 pp |
| Q2 2024 | 2024-06-30 | −62.92% | +358.84 pp |
| Q1 2024 | 2024-03-31 | −45.62% | — |
| Q4 2023 | 2023-12-31 | −92.67% | — |
| Q3 2023 | 2023-09-30 | −77.06% | — |
| Q2 2023 | 2023-06-30 | −421.76% | — |
Mira Pharmaceuticals return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Mira Pharmaceuticals's return on equity increased from −634.30% to −165.87%, a change of +468.43 percentage points. The latest reported quarter, Q2 2026, shows −13.80%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mira Pharmaceuticals source filings ↗